Interim Report January - September 2009

GROUP FINANCIAL PERFORMANCE JANUARY - SEPTEMBER • Net sales were SEK 64.1 million • Operating income (EBIT) was SEK 18.2 million • Net income after tax was SEK 10.8 million • Results of investing activities amounted to SEK 0.0 million • Earnings per share, basic and diluted, were SEK 0.75 • Equity per share was SEK 38.77 • Equity/assets ratio was 80 percent PARENT COMPANY FINANCIAL PERFORMANCE JANUARY - SEPTEMBER • Results of investing activities amounted to SEK 0.0 million (0.0) • Other income totaled SEK 3.5 million (2.9) • Net loss after tax was SEK 10.3 million (-9.3) KEY EVENTS IN THE THIRD QUARTER • Olerup SSP’s entire HLA-typing range now ready for sales in the US • Likvor’s CELDATM instrument is CE marked • ONCOlog Medical received major order for the PatLog® system from medical center in Prague • ONCOlog Medical received breakthrough order for table plates in the U.S. • LinkMed renegotiated additional purchase price for Olerup SSP • LinkMed completed acquisition of Qiagen Vertriebs GmbH • LinkMed strengthened its global distribution company in collaboration with NorDiag LINKMED CEO INGEMAR LAGERLÖFS COMMENTS ON THE THIRD QUARTER: “The group reports a strong cash flow from operations for the first nine months of the year. One year after the acquisition of Olerup SSP we have demonstrated that we are successful in increasing sales for the company. AbSorber’s launch in the U.S. has exceeded expectations and our newly established distribution company gives Olerup SSP and AbSorber’s products the focus they need. It will be extremely interesting to follow Likvor’s launch of CELDA. This product is in demand and will help medical centers to establish a correct diagnosis, leading to the right treatment for NPH patients.”